Welcome to our dedicated page for Relmada Therapeutics SEC filings (Ticker: RLMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Relmada Therapeutics, Inc. uses SEC filings to document its clinical-stage biotechnology business, Nasdaq-listed common stock, governance, operating results, and capital structure. Its Form 8-K filings cover financial results, Regulation FD presentations, FDA feedback and NDV-01 clinical or regulatory disclosures, material agreements, executive employment arrangements, and equity financing activity.
Proxy filings address board matters, executive compensation, shareholder voting items, and related governance disclosures. Capital-structure records include common stock and pre-funded warrant disclosures associated with financing transactions.
Relmada Therapeutics CEO and director Sergio Traversa reported buying 27,500 shares of the company’s common stock in multiple open market transactions at a weighted average price of $4.12 per share, with individual purchase prices ranging from $4.10 to $4.12.
Following these purchases, he beneficially owns 1,300,000 common shares directly. Traversa was also granted 1,198,000 stock appreciation rights with a conversion price of $4.06, each linked to one share of common stock. These rights vest in 16 equal quarterly installments beginning on March 12, 2026 and expire on December 12, 2035, with 1,198,000 derivative securities shown as beneficially owned after the transaction.
Relmada Therapeutics, Inc.'s chief financial officer reported buying 11,665 shares of common stock on December 15, 2025 at $4.12 per share, bringing his directly held stake to 800,000 shares. In a separate transaction on December 12, 2025, he was granted 828,000 stock appreciation rights with a $4.06 exercise price, each linked to one share of common stock and expiring on December 12, 2035. These rights begin vesting on March 12, 2026 in 16 equal quarterly installments, providing additional long-term equity-based compensation tied to the company’s stock.
Relmada Therapeutics, Inc. reported that one of its officers with the title "CA and CO" received 828,000 stock appreciation rights12/12/2025$4.0603/12/202612/12/203516 equal quarterly installments828,000 derivative securities
Relmada Therapeutics director Fabiana Fedeli reported receiving a grant of 164,000 stock appreciation rights on December 12, 2025. These derivative securities relate to Relmada Therapeutics common stock and carry an exercise price of $4.06 per right. The award was reported as an acquisition transaction and is held with direct ownership.
The stock appreciation rights are scheduled to vest in 16 equal quarterly installments, commencing on March 12, 2026, providing a staged vesting profile over time. The instruments become exercisable starting March 12, 2026 and have an expiration date of December 12, 2035, giving a long-dated window in which they may be exercised.
Relmada Therapeutics director John Glasspool reported a new equity award in the form of stock appreciation rights. On 12/12/2025, he was granted 164,000 stock appreciation rights with a conversion or exercise price of $4.06, each tied to one share of Relmada common stock.
The award is structured as a long-term incentive. It begins vesting on March 12, 2026, in 16 equal quarterly installments and expires on 12/12/2035. Following this grant, Glasspool beneficially owns 164,000 derivative securities directly, all linked to Relmada’s common stock.
Relmada Therapeutics director and COO Paul Kelly reported receiving 828,000 stock appreciation rights tied to the company’s common stock. These rights were granted on December 12, 2025 with an exercise price of $4.06 and expire on December 12, 2035.
The stock appreciation rights vest in 16 equal quarterly installments starting March 12, 2026, so portions of the award become exercisable over time. After this grant, Kelly beneficially owns 828,000 derivative securities directly, linking part of his compensation to Relmada’s future share performance.
Relmada Therapeutics, Inc. reported an insider equity award to one of its directors. On 12/12/2025, the director received stock appreciation rights tied to 164,000 shares of common stock with a base price of $4.06 per share.
These stock appreciation rights begin vesting in 16 equal quarterly installments starting on March 12, 2026, and are scheduled to expire on December 12, 2035. The award was reported as directly owned by the director.
Relmada Therapeutics, Inc. reported that its Board of Directors approved amended and restated employment agreements for its executive officers on December 12, 2025. The updated contracts cover Chief Executive Officer Sergio Traversa, Chief Operating Officer Paul Kelly, Chief Financial Officer Maged Shenouda, and Chief Accounting and Compliance Officer Charles Ence, and are stated to become effective as of January 1, 2026. The company explains that, except for the revisions reflected in these new agreements, the material terms remain the same as those previously described in earlier SEC disclosures, and the complete agreements are filed as exhibits.
Relmada Therapeutics (RLMD) furnished an update and preliminary, unaudited quarterly financial results via a press release and scheduled a conference call to discuss them. The company plans to file complete unaudited financial statements and notes in its upcoming Form 10‑Q.
The press release was provided as Exhibit 99.1 and a refreshed corporate presentation as Exhibit 99.2. Under the furnished status, this information is not deemed filed under the Exchange Act except as specifically incorporated by reference. A conference call and webcast were set for November 13, 2025 at 4:30 PM ET to review the update and results.
Relmada Therapeutics (RLMD) filed its Q3 2025 10‑Q showing narrower losses and a refocused pipeline. Operating expenses fell to $10.3 million from $23.0 million a year ago, driving a net loss of $10.1 million versus $21.7 million. For the nine months, the net loss was $37.5 million, with operating cash outflow of $31.2 million. At September 30, cash was $1.38 million and short‑term investments were $12.50 million.
The company alleviated going‑concern uncertainty after closing an underwritten offering on November 5 for 40.14 million shares and 5.32 million pre‑funded warrants, generating approximately $94 million in net proceeds (before other expenses, excluding warrant exercises). Nasdaq confirmed minimum bid price compliance on September 15.
Pipeline shifted to two assets: NDV‑01 (intravesical gemcitabine/docetaxel) in Phase 2 for NMIBC showed a 92% “anytime” complete response among 25 evaluable patients and secured FDA alignment to pursue two Phase 3 studies, targeted to begin in H1 2026. Sepranolone was acquired for €3.0 million (with $2.756 million paid) and is expected to enter a Phase IIb study in Prader‑Willi Syndrome in H1 2026. Earlier esmethadone and psilocybin programs were terminated.